Stock Ratings / Health Care / CADL / insiders

SLBT (47) AURA (40) IAM (50) DBVT (26) ⌘ Pro Terminal →

Candel Therapeutics Inc. (CADL) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$8.65 -0.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.63

Candel Therapeutics Inc. (CADL) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $661.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.63 (-0.23%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CADL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY CADL SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (32% of score)

FRED Regime × Technicals: 45% of 52W Range • RSI-14 at 37.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$9.94-17.6% Next Q

Q2 (-2Q)

Grade D$8.19-2% Next Q

Q3 (-1Q)

Grade D$8.03+7.7% Next Q

Current

Grade D-$8.65-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CADL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CADL currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.68) and Max Pain ($9.08) forces dealer call-delta covering toward $14.70.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CADL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CADL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CADL Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CADL)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CADL. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CADL)

✓Walkthrough of CADL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CADL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +39.97%📐 HORIZONTAL RANGE

2026-10-30O $8.56H $8.65L $8.16C $8.65VOL 779.2K

RES: $16.96SUP: $7.62SMA50: $10.68SMA200: $8.28

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CADL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CADL Butterfly Map → + Track CADL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CADL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CADL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CADL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CADL)

Health Care Rank #704 of 1016 ⚔️ SLBT vs CADL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CADL vs. SLBT, AURA, IAM, DBVT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Candel Therapeutics Inc. (CADL) ranks #704 by composite RQD confidence (38/100, grade D-) and #406 by equity capitalization ($661.9M). Within this direct 5-issuer industry benchmark cohort, CADL leads on earnings valuation at N/A trailing P/E, while CADL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with CADL at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CADL ACTIVE Candel Therapeutics Inc.	D-	38/100	—	—	-35.0%	-0.23%	$661.9M	Benchmark Subject
SLBT SL Science Holding Limited	D	47/100	—	—	—	-3.31%	$656.1M	/slbt-vs-cadl →
AURA Aura Biosciences Inc.	D-	40/100	—	—	-35.0%	-1.64%	$652.8M	/aura-vs-cadl →
IAM Iambic Therapeutics Inc.	D	50/100	—	—	—	-3.38%	$676.9M	/iam-vs-cadl →
DBVT DBV Technologies S.A.	E	26/100	—	—	-35.0%	-3.38%	$647.0M	/dbvt-vs-cadl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001841387

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Candel Therapeutics Inc. (CADL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$38.2M, operating cash flow of -$38.3M, and free cash flow of -$38.9M (-43.9% YoY). On the balance sheet, CADL closed FY2025 with $125.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$38.2M	-$38.3M	-$38.9M	$125.2M	—
FY2024 (FY)	2024-12-31	$0	-$55.2M	-$27.0M	-$27.0M	$106.9M	$1.7M
FY2023 (FY)	2023-12-31	$0	-$37.9M	-$34.2M	-$34.2M	—	—

3. CADL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CADL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Candel Therapeutics Inc. (NASDAQ: CADL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $8.65 (-0.23% 1D, market cap $661.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CADL ranks #704 in composite RQD confidence.

How does CADL compare to SLBT and AURA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CADL carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SLBT (SL Science Holding Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $656.1M) and AURA (Aura Biosciences Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M). Among the 5-stock peer group, CADL leads on earnings multiple (N/A) while CADL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CADL?

Per CADL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001841387), Candel Therapeutics Inc. generated $0 in revenue, -$38.2M in net income, and -$38.9M in free cash flow against $125.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CADL trading relative to its 50-day, 200-day, and 52-week technical levels?

CADL last traded at $8.65 (-0.23% on volume of 740,973 shares), positioning the stock -19.01% below its 50-day simple moving average ($10.68) and +4.47% above its 200-day simple moving average ($8.28). Across its 52-week range of $4.35 to $14.00, CADL sits at the 44.6% percentile with a 14-day RSI of 37.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.57 to $9.73).

CADL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CADL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CADL leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: CADL RQD Cockpit CADL 12M Forecast CADL Earnings & Move CADL Dividends & DRIP CADL Insiders & 13F CADL Whale Options CADL Profit Sankey CADL News & Why